Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jean‐Laurent Colas"'
Autor:
Justine Perino, Virginie Corand, Elise Laurent, Hélène Théophile, Ghada Miremont‐Salamé, Antoine Pariente, Jean‐Laurent Colas, Thierry Couffinhal, Francesco Salvo
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Wiley, In press, ⟨10.1002/phar.2706⟩
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022, Online ahead of print. ⟨10.1002/phar.2706⟩
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Wiley, In press, ⟨10.1002/phar.2706⟩
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022, Online ahead of print. ⟨10.1002/phar.2706⟩
International audience; Background: Monoclonal antibodies acting on the calcitonin gene related peptide or its receptor (CGRP-mabs) are novel drugs for resistant migraine prophylaxis. As CGRP-mabs cause inhibition of vasodilatation, their use is rese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::970c6fc933ef14ca255d1785120a9290
https://hal.archives-ouvertes.fr/hal-03696664/document
https://hal.archives-ouvertes.fr/hal-03696664/document
Autor:
Jean-Laurent Colas, Michel Slama, Michel Andrejak, Lionel Hary, Thibault Collin, Michel E. Safar, Bouchra Colas, Marie-Luce Arnould, Henri Masson
Publikováno v:
Fundamental & Clinical Pharmacology. 14:363-368
In vitro experiments were designed to assess the inhibitory effect of the thiazide diuretics methyclothiazide (MCTZ), the hydrochlorothiazide (HCTZ), and the thiazide-related diuretic indapamide (IND) on contractile responses to norepinephrine (NE) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6194933ff7b92a6f8850e57cf4cc41
https://doi.org/10.1111/j.1472-8206.2000.tb00417.x
https://doi.org/10.1111/j.1472-8206.2000.tb00417.x
Autor:
Marcel Peltier, Jean Philippe M. Lesbre, Jean Laurent Colas, Micheèle C.Iannetta Peltier, Christophe Tribouilloy, Maurice E. Sarano
Publikováno v:
Chest. 121(5)
Study objective: Lipoprotein(a) (Lp[a]) level is a risk factor for ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. However, few data are available concerning the relationship between Lp(a) level and severity of thora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74cd9b070e6e0c8041c2df8114f8b244
https://pubmed.ncbi.nlm.nih.gov/12006448
https://pubmed.ncbi.nlm.nih.gov/12006448